BACKGROUND: Tumors have heterogeneous properties, which could be explained by the existence of hierarchically and biologically distinct tumor cells such as tumor-initiating cells (TICs). This model is clinically important, as TICs are promising targets for cancer therapies. However, TICs in spontaneous B-cell lymphoma have not been conclusively identified. HYPOTHESIS/ OBJECTIVES: Tumor cells with a progenitor phenotype exist in B-cell lymphoma, reflecting a hierarchical organization. ANIMALS: Twenty-eight client-owned dogs with previously untreated B-cell lymphoma and 6 healthy dogs. METHODS: This was a prospective study. Flow cytometry was used to identify lymphoid progenitor cells (LPCs) that coexpressed hematopoietic progenitor antigens CD34, CD117, and CD133, with lymphoid differentiation markers CD21 and/or CD22 in B-cell lymphoma. The polymerase chain reaction for antigen receptor rearrangements was used to analyze clonality and relatedness of tumor populations. A xenograft model with NOD/SCID/IL-2Rγ(-/-) mice was adapted to expand and serially transplant primary canine B-cell lymphoma. RESULTS: LPCs were expanded in lymph nodes from 28 dogs with B-cell lymphoma compared with 6 healthy dogs (P= .0022). LPCs contained a clonal antigen receptor gene rearrangement identical to that of the bulk of tumor cells. Canine B-cell lymphoma xenografts in recipient mice that maintained LPCs in the tumors were recurrently observed. CONCLUSIONS AND CLINICAL IMPORTANCE: These results suggest the presence of a hierarchy of tumor cells in B-cell lymphoma as has been demonstrated in other cancers. These findings have the potential to impact not only the understanding of lymphoma pathogenesis but also the development of lymphoma therapies by providing novel targets for therapy.
BACKGROUND:Tumors have heterogeneous properties, which could be explained by the existence of hierarchically and biologically distinct tumor cells such as tumor-initiating cells (TICs). This model is clinically important, as TICs are promising targets for cancer therapies. However, TICs in spontaneous B-cell lymphoma have not been conclusively identified. HYPOTHESIS/ OBJECTIVES:Tumor cells with a progenitor phenotype exist in B-cell lymphoma, reflecting a hierarchical organization. ANIMALS: Twenty-eight client-owned dogs with previously untreated B-cell lymphoma and 6 healthy dogs. METHODS: This was a prospective study. Flow cytometry was used to identify lymphoid progenitor cells (LPCs) that coexpressed hematopoietic progenitor antigens CD34, CD117, and CD133, with lymphoid differentiation markers CD21 and/or CD22 in B-cell lymphoma. The polymerase chain reaction for antigen receptor rearrangements was used to analyze clonality and relatedness of tumor populations. A xenograft model with NOD/SCID/IL-2Rγ(-/-) mice was adapted to expand and serially transplant primary canineB-cell lymphoma. RESULTS: LPCs were expanded in lymph nodes from 28 dogs with B-cell lymphoma compared with 6 healthy dogs (P= .0022). LPCs contained a clonal antigen receptor gene rearrangement identical to that of the bulk of tumor cells. CanineB-cell lymphoma xenografts in recipient mice that maintained LPCs in thetumors were recurrently observed. CONCLUSIONS AND CLINICAL IMPORTANCE: These results suggest the presence of a hierarchy of tumor cells in B-cell lymphoma as has been demonstrated in other cancers. These findings have the potential to impact not only the understanding of lymphoma pathogenesis but also the development of lymphoma therapies by providing novel targets for therapy.
Authors: Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl Journal: Cancer Res Date: 2006-09-21 Impact factor: 12.701
Authors: Anna van Rhenen; Nicole Feller; Angèle Kelder; August H Westra; Elwin Rombouts; Sonja Zweegman; Marjolein A van der Pol; Quinten Waisfisz; Gert J Ossenkoppele; Gerrit Jan Schuurhuis Journal: Clin Cancer Res Date: 2005-09-15 Impact factor: 12.531
Authors: T Lapidot; C Sirard; J Vormoor; B Murdoch; T Hoang; J Caceres-Cortes; M Minden; B Paterson; M A Caligiuri; J E Dick Journal: Nature Date: 1994-02-17 Impact factor: 49.962
Authors: Roberto Pallini; Lucia Ricci-Vitiani; Giuseppe Luigi Banna; Michele Signore; Dario Lombardi; Matilde Todaro; Giorgio Stassi; Maurizio Martini; Giulio Maira; Luigi Maria Larocca; Ruggero De Maria Journal: Clin Cancer Res Date: 2008-12-15 Impact factor: 12.531
Authors: Elsa Quintana; Mark Shackleton; Michael S Sabel; Douglas R Fullen; Timothy M Johnson; Sean J Morrison Journal: Nature Date: 2008-12-04 Impact factor: 49.962
Authors: Sarah Culver; Daisuke Ito; Luke Borst; Jerold S Bell; Jaime F Modiano; Matthew Breen Journal: Vet Clin Pathol Date: 2013-06-25 Impact factor: 1.180
Authors: Kipp Weiskopf; Katie L Anderson; Daisuke Ito; Peter J Schnorr; Hirotaka Tomiyasu; Aaron M Ring; Kristin Bloink; Jem Efe; Sarah Rue; David Lowery; Amira Barkal; Susan Prohaska; Kelly M McKenna; Ingrid Cornax; Timothy D O'Brien; M Gerard O'Sullivan; Irving L Weissman; Jaime F Modiano Journal: Cancer Immunol Res Date: 2016-11-14 Impact factor: 11.151
Authors: Daisuke Ito; Aric M Frantz; Christina Williams; Rachael Thomas; Robert C Burnett; Anne C Avery; Matthew Breen; Nicola J Mason; Timothy D O'Brien; Jaime F Modiano Journal: Leuk Lymphoma Date: 2012-02-03
Authors: A M Frantz; A L Sarver; D Ito; T L Phang; A Karimpour-Fard; M C Scott; V E O Valli; K Lindblad-Toh; K E Burgess; B D Husbands; M S Henson; A Borgatti; W C Kisseberth; L E Hunter; M Breen; T D O'Brien; J F Modiano Journal: Vet Pathol Date: 2012-11-02 Impact factor: 2.221
Authors: Daisuke Ito; Michael Childress; Nicola Mason; Amber Winter; Timothy O'Brien; Michael Henson; Antonella Borgatti; Mitzi Lewellen; Erika Krick; Jane Stewart; Sarah Lahrman; Bartek Rajwa; Milcah C Scott; Davis Seelig; Joseph Koopmeiners; Stephan Ruetz; Jaime Modiano Journal: F1000Res Date: 2015-02-11